Clinical Trials: Gastrointestinal Cancer
Treatment Trials
GIST
Therapeutic Area: Primary GastroIntestinal Stromal Tumor (GIST)
Principal Investigator: Dr. Susan Tannenbaum
Title: ECOG Z9001: A Phase III Randomized Double-blind Study of Adjuvant STI571 (Gleevec) Versus Placebo in Patients Following The Resection of Primary GastroIntestinal
Stromal Tumor (GIST)
Description: To determine whether patients with resected primary GIST who are randomized to receiving Gleevec have longer recurrence-free survival as compared to the
patients randomized to the Placebo Arm.
Length/Duration: Treatment for 1 years, follow-up for 9 years
Compensation: None
Location: Neag Comprehensive Cancer Center at the University of Connecticut Health Center
For more information, patient benefits, and to learn if you qualify:
please call 860-679-3066 or send an email to dnoel@uchc.edu
IRB #: 03-305
Sponsor: National Surgical Breast and Bowl Project (NSABP)
 Pancreas
Therapeutic Area: Pancreas
Principal Investigator: Dr. Susan Tannenbaum
Title: ECOG E4201: A Randomized Phase III Study of Gemcytabine in Combination with Radiation Therapy versus Gemcytabine Alone in Patients with Localized, Unresectable
Pancreatic Cancer
Description: The major purpose(s) of this research study are to: 1) find out what the effects that gemcitabine and radiation therapy have on pancreatic cancer for
complete or partial improvement compared to Gemcitabine alone, and 2) describe the toxicity related to the use of this drug in combination with radiation therapy in patients with
pancreatic cancer
Length/Duration: Depends on response to therapy
Compensation: None
Location: Neag Comprehensive Cancer Center at the University of Connecticut Health Center
For more information, patient benefits, and to learn if you qualify:
please call 860-679-3066 or send an email to dnoel@uchc.edu
IRB #: 03-376
Sponsor: National Surgical Breast and Bowl Project (NSABP) |
Research
done today will be the standard treatments of tomorrow.